CAR-Modified Treg Cells for Autoimmune Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for autoimmune and alloimmune diseases, such as graft-vs-host disease, primarily treat symptoms rather than the underlying disease, and there is a need for more effective treatments that target the actual cause.
Innovation Solution
A pharmaceutical composition comprising modified human regulatory T cells (Treg cells) engineered to express a chimeric antigen receptor (CAR) construct specific for CD19, which are administered to patients to replicate in vivo and form memory T cells that target B cells and plasma cells, thereby reducing disease symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies are used for autoimmune and alloimmune diseases, then treatment is provided, but the therapies only treat symptoms rather than the underlying disease
Solution Approach 1:
T cells are pre-engineered ex vivo to express CAR constructs specific for disease-related antigens (such as CD19 in SLE) before administration. This preliminary genetic modification enables the cells to immediately recognize and target pathological cells upon injection, addressing the root cause rather than just symptoms.
Solution Approach 2:
The patent uses CAR-modified T cells as intermediary agents that bridge the gap between the immune system and the pathological cells. These engineered T cells serve as mediators that specifically recognize target antigens on B cells or plasma cells and eliminate them, thereby treating the underlying autoimmune or alloimmune disease mechanism.
2Reliability
If CAR-modified T cells are used to target specific antigens, then disease-specific treatment is achieved, but there is risk of off-target effects
Solution Approach 1:
The CAR construct is designed with high specificity for a particular antigen (e.g., CD19) expressed on target cells. The antigen-binding domain of the CAR is engineered to recognize only the intended target, ensuring that the therapeutic effect is localized to specific pathological cells while sparing healthy cells that do not express the target antigen.
Solution Approach 2:
The patent employs safety mechanisms including suicide genes (e.g., HSV-TK) that can be activated by ganciclovir to induce apoptosis in CAR-T cells if off-target effects occur. This feedback mechanism allows for control and reversal of the therapeutic effect if harmful off-target cytotoxicity is detected, thereby mitigating safety risks.
3Reliability
If high doses of T cells are administered to ensure therapeutic effect, then treatment efficacy is improved, but the complexity of dosing and administration increases
Solution Approach 1:
The patent utilizes the ability of CAR-T cells to self-expand and self-sustain within the patient's body. By optimizing the initial dose and culture conditions ex vivo, the cells can proliferate in vivo to achieve therapeutic levels without requiring continuous high-dose administration. This transforms the dosing strategy from continuous external input to a single or limited administration with in vivo amplification.
Data Source
Figure 1~1D
Figure 2
Figure 3A~3B
AI summary
Provided herein are methods and materials for treating autoimmune diseases and alloimmune diseases.